Epstein-Barr virus nuclear antigen 1-derived peptide-MHC complex (EBNA1-pMHC)

The Epstein-Barr virus nuclear antigen 1 (EBNA1)-derived peptide-MHC complex is a critical immunological target for treating EBV-associated malignancies and autoimmune conditions. EBNA1 is a multifunctional viral protein essential for the replication and persistence of the EBV genome in host cells, and it is uniquely expressed in all EBV-related cancers, including Nasopharyngeal carcinoma and various lymphomas (PMID: 21507823). Peptides derived from EBNA1 are processed and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, allowing the immune system to identify and eliminate infected cells (PMID: 31434705). Therapeutic interventions, such as adoptive T-cell therapies like Tabelecleucel and TCR-engineered T cells, specifically recognize these pMHC complexes to trigger a cytotoxic immune response. Despite the virus's mechanism of using a Gly-Ala repeat (GAr) domain to limit its own degradation and MHC I presentation, sufficient EBNA1 epitopes are displayed to make it a viable target for immunotherapy. Furthermore, recent evidence has linked the immune response against EBNA1-pMHC to the pathogenesis of Multiple Sclerosis through molecular mimicry with host proteins like GlialCAM (PMID: 35025605).

Other names

EBNA1-HLA complexEBNA1 peptide-HLA complexEBNA1-derived epitopesEBV nuclear antigen 1-MHC complex

Recognition by T-cell receptors (TCRs) or TCR-like antibodies leading to targeted lysis of EBV-positive cells through the release of perforins and granzymes.